Poster, Podium & Video Sessions
Presentation Authors: BOB YANG*, Steve Foley, Reading, United Kingdom
Introduction: Urinary tract infections (UTI) are one of the most prevalent conditions worldwide, with incidence increasing with age. Oestrogen decrease in post-menopausal women lowers levels of Lactobacillus within the vaginal microenvironment, a key factor in synthesising lactic acid and the creation of the acidic vaginal defence. These women often require long-term antibiotics. However with the rising incidence of bacterial resistance, there is a need to find alternative therapies.
FemTouch is a thermal ablative laser, which when applied to the vagina, induces a histologically proven rejuvenation of the lining to a pre-menopausal state, similar to oestrogen therapy. FemTouch is used by gynaecologists to treat atrophic vaginitis and is favourable in women unsuitable for oestrogen therapy.
We present the first experience in the United Kingdom (UK) of using FemTouch to treat recurrent UTIs in a preliminary cohort of women.
Methods: 9 postmenopausal women with recurrent UTIs received 3 courses of FemTouch (Lumenis, Israel) at monthly intervals. Total follow up for 6 months assessed rates of UTI, changes in vaginal pH and assessment of vaginal health using subjective measures of vaginal fluid/moisture, firmness and elasticity.
No patients received concurrent antibiotic or hormonal therapy during the treatment or follow up period.
Results: Pre-treatment, the patients averaged one UTI every 6 weeks. To date only one patient has had a recurrence of UTI after treatment.
The average vaginal pH, displayed in table 1, improved with treatment. All patients described marked improvements in menopausal vaginal symptoms, as shown by their average vaginal health scores in table 2.
All patients described the pain of the procedure as 1/10 on average throughout.
Conclusions: Our preliminary results show that FemTouch is both effective and well tolerated in the treatment of recurrent UTIs in postmenopausal UK women, suggesting FemTouch may be a viable alternative to antibiotic prophylaxis. In addition, laser treatment made a big difference to patients general vaginal health, restoring it in the patients view to a pre-menopausal state.
There seems to be enough merit to establish a national multi-centre trial to evaluate the efficacy of FemTouch in larger groups of patients for a longer follow up period.
Source Of Funding: None
Royal Berkshire Hospital UK
Mr Bob Yang MRCS MBBS BSc (Hons)
Graduated Imperial College London. Completed Foundation Training in Health Education Thames Valley. Undergoing Core Surgical Trainee in Oxford School of Surgery. Currently working in Royal Berkshire Hospital, Reading, UK
Specialty interest in Urological Surgery. Enthusiastic in research, technology and teaching skills. Keen snowboarder and badminton player!
Saturday, May 13
7:00 AM – 9:00 AM